Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- HTA Method Shifts & Pricing TrendsEpisode 113 — 16 September 2026Examining evolving HTA methodologies, adaptive pathways, and US operational challenges in drug pricing and evidence generation.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- Access Erosion Signals & Value FrameworksEpisode 112 — 15 September 2026Analyzing US healthcare access erosion signals, subcutaneous Alzheimer's therapy implications, insulin pricing competition impact, and early-phase HEOR strategy shifts.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Evolution & Access PressuresEpisode 111 — 14 September 2026CMS Part D redesign operational hurdles, ICER's Alzheimer's evidence framework evolution, EMA's rare disease pathway expansion, and FDA gene therapy designation updates reshape evidence strategies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HCA Warning, Leqembi Shift, PBM ScrutinyEpisode 110 — 13 September 2026HCA's profit warning signals US healthcare access challenges; new Leqembi formulation and FTC insulin settlement reshape value arguments; ICER expands early scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- Global HTA Shifts & Digital HealthEpisode 109 — 12 September 2026Examining WHO's new health technology framework for resource-limited settings, Australia's TGA digital therapeutics updates, Canada's CADTH combination products pilot, and NICE's expanding global influence on HTA standards.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- HCA Warning & Leqembi ShiftEpisode 108 — 11 September 2026HCA's profit warning signals US hospital access erosion; subcutaneous Leqembi transforms Alzheimer's value assessments; FTC targets insulin pricing practices; ICER expands early-phase scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- CMS Gene Therapy Coverage & RWE IntegrationEpisode 107 — 10 September 2026CMS Part D gene therapy coverage shifts, FDA RWE guidance for post-marketing studies, NICE digital therapeutics framework updates, and EU Critical Medicines Act HTA timeline acceleration.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HTA Evolution & AI GovernanceEpisode 106 — 09 September 2026Examining emerging HTA frameworks in Asia-Pacific, RWE barriers in Latin America, gene therapy value strategies, and digital therapeutics integration hurdles.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
- Access Erosion & Value SignalsEpisode 105 — 08 September 2026HCA's profit warning signals access challenges; new Leqembi formulation and FTC settlement reshape pricing dynamics; ICER expands early-phase advice to align HEOR strategy.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- Profit Warnings & Insulin PricingEpisode 104 — 07 September 2026HCA's profit warning signals access erosion, subcutaneous Leqembi challenges cost-effectiveness, FTC insulin settlement reshapes PBMs, and ICER expands early-phase advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.